The global ankylosing spondylitis treatment market is projected to exhibit considerable growth during the forecast period. Ankylosing spondylitis is an inflammatory disease that leads to the fusion of some small bones of the spine (vertebrae) making the spine less flexible. The rising geriatric population is expected to be a major cause responsible for ankylosing spondylitis. The rising focus of the players operating in the ankylosing spondylitis market towards investment in R&D of drugs for its treatment along with increasing FDA approvals is expected to be the key factor contributing towards the growth of the market across the globe. AbbVie, Inc., Allergen Inc., Eli Lilly and Co., Merck & Co. Inc., Sanofi SA, Pfizer Inc., Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Endo Health Solutions, Inc., and so on are the major players operating in the global ankylosing spondylitis treatment market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ankylosing-spondylitis-treatment-market
These market players are making a hefty investment in their R&D sector to perform drug development for the launch of new and advanced drugs for the treatment of this disorder. For instance, in October 2019, Novartis International AG, a pharmaceutical company had received approval from European Commission (EC) to perform the up-titration of Cosentyx (secukinumab) to 300 mg for patients with active ankylosing spondylitis. The approval is based on data from MEASURE 3, a three-year study that identified the efficacy and tolerability of Cosentyx in ankylosing spondylitis patients.
In August 2019, Eli Lilly and Company, an American pharmaceutical company had received the US FDA approval for Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis (r-axSpA). Taltz (ixekizumab) injection 80 mg/mL is the third indication of the Talz which was approved for the treatment of moderate to severe plaque psoriasis in adult patients and then approved in December 2017 for the treatment of psoriatic arthritis.
In August 2019, AbbVie’s Pharmaceutical, a research-based global biopharmaceutical company, had received US FDA approval for RINVOQ (upadacitinib). RINVOQ (upadacitinib) is a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis. In December 2019, RINVOQ (upadacitinib) is proved to be effective in a Phase 2/3 trial shows for the treatment of adults with active ankylosing spondylitis who failed to respond to or are not eligible for non-steroidal anti-inflammatory drugs (NSAIDs),.
Current Market Trends Covered in the Market Report.
- North America is anticipated to hold a major market share during the forecast period.
- The rising awareness among people related to the treatment of the ankylosing spondylitis.
- Partnerships, collaborations, and new product launches – key drivers of competition in the market.
Global Ankylosing Spondylitis Treatment Market Segmentation
By Drug
- Secukinumab
- Adalimumab
- Golimumab
- Infliximab
- Etanercept
- Certolizumab Pegol
- Other
A full report of Ankylosing Spondylitis Treatment Market is available at: https://www.omrglobal.com/industry-reports/ankylosing-spondylitis-treatment-market
Global Ankylosing Spondylitis Treatment Market Segmentation by region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie, lnc.
- Allergen, Inc.
- Amgen, Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb, Co.
- Cadila Healthcare, Ltd.
- Eli Lilly and Co.
- Endo Health Solutions, Inc.
- Hoffmann-La Roche, Ltd.
- Ferring B.V.
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Purdue Pharma L.P.
- Sanofi S.A.
- Torrent Pharmaceuticals, Ltd.
- Valeant Pharmaceuticals International Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research